Seeking Alpha

Idenix Pharmaceuticals (IDIX) says the USPTO's Patent Trial and Appeal Board has decided against...

Idenix Pharmaceuticals (IDIX) says the USPTO's Patent Trial and Appeal Board has decided against it in the first phase of its two-stage interference process concerning one of IDIX's patent applications, and an issued patent owned by Gilead Pharmasset (GILD) that covers certain 2'-methyl- 2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus. Shares -13% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs